EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($0.52), in-line with the analyst estimate of ($0.52). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $10.89 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.